The treatment of colorectal cancer is one of the most challenging problems of modern oncology due to the high incidence both in the Republic of Belarus and in the whole world. Since chemotherapy remains the main method of treatment of metastatic disease, there remains a need to develop and introduce into clinical practice new effective methods of chemotherapy for colorectal cancer. This article presents the interim results of treatment of colorectal cancer patients in Minsk City Clinical Oncologic Dispensary with the use of maintenance metronomic chemotherapy, who were enrolled from 2016 till 2019 (n = 60). Metronomic regimen consisted of oral capecitabine 500 mg 3 times a day and oral cyclophosphane 50 mg daily. The control arm consisted of mCRC patients who received the same induction chemotherapy without maintenance from 2011 till 2015 (n = 70). Median follow-up time was 18,5 months. Median progression-free survival (PFS) was 9.0 and 7.4 months in the maintenance and control arms respectively. Median overall survival (OS), counted from the beginning of induction chemotherapy, is currently 22.9 months in the maintenance arm, and 14.7 months in control. Low expression levels of genes, encoding enzymes TS (thymidylate synthetase), DPD (dihydropyrimidine dehydrogenase) and receptor VEGFR1, high expression level of gene TP (thymidylate phosphorylase), as well as low levels of tumor markers CEA and СА 19-9 are the prognostic factors of sensitivity to metronomic chemotherapy given to colorectal cancer patients. Based on these data, we identified a group of patients who are recommended to use this method of treatment.

1. Океанов, А. Е. Статистика онкологических заболеваний в Республике Беларусь (2004-2013) / А. Е. Океанов, П. И. Моисеев, Л. Ф. Левин; под ред. О. Г. Суконко. – Минск: РНПЦ ОМР им. Н. Н. Александрова, 2015. – С. 136–141.

2. Чубенко, В. А. Метрономная терапия злокачественных опухолей / В. А. Чубенко, В. М. Моисеенко // Материалы XII Российского онкологического конгресса. – Москва; издательская группа ГУ РОНЦ им. H. H. Блохина РАМН: 2008. – С. 103–106.

3. Browder T., Butterfield C. E., Kraling B. M. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60(7):1878-1886.

4. Chibaudel, B., Maindrault-Goebel, F., Lledo, G., Mineur, L., André, T., Bennamoun, M., & de Gramont, A. (2009). Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. Journal of Clinical. Oncology, 27(34), 5727-5733. doi: 10.1200/JCO.2009.23.4344.

5. Drevs J., Fakler J., Eisele S. et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004; 24: 1759-1763.

6. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374–1403.

7. Gnoni A., Silvestris N., Licchetta A. et. al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? 2015; 95(1):46-61.

8. Kerbel R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13(1):31-6.

9. Lien K., Georgsdottir S., Sivanathan L., Chan K., Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur. J .Cancer 2013; 49(16):3387-3395.

10. Louvet C, Coudray AM, Tournigand C, et al. Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice. Anticancer Drugs 2000; 11:579-82.

11. Pasquier E., Kavallaris M., André N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol 2010; 7(8): 455-465.

12. Stöhlmacher J. Pharmacogenetics in gastrointestinal tumors. Onkologie. 2005;28: 435-440